Smart Contact Lenses and Stylish Glasses for Next Generation AR / VR

1. SMART CONTACT LENSES
and STYLISH GLASSES for
AR / VR
Innovega Crowdfunder Presentation
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 1
Innovega

2. Forward-looking statements
• This presentation contains forward-looking statements and information relating to, among
other things, Innovega Inc, its business plan and strategy, and its industry.
• These statements reflect management’s current views with respect to future events based on
information currently available and are subject to risks and uncertainties that could cause the
company’s actual results to differ materially.
• Investors are cautioned not to place undue reliance on these forward-looking statements as
they are meant for illustrative purposes and they do not represent guarantees of future results,
levels of activity, performance, or achievements, all of which guarantees cannot be made.
• Moreover, no person or entity assumes responsibility for the accuracy and completeness of
these forward-looking statements, and no persons or entities are under any duty to update
any such statements to conform them to actual results.
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 2
I n n o v e g a

3. We deliver Smart Contact Lenses
and AR/VR Glasses that wearers
want and need
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 3
I n n o v e g a

4. • $2M investment
• Fabrication tooling
completed
Traction
• $5.5M Revenue from
National Science Foundation,
DARPA, and U.S. Army
• $1M from SeedInvest
• IRB approval for human
use testing of contact lens
and display eyewear
• Four phase II clinical
trials at The Ohio
State University
• Revenue from National Eye Institute
• 13 patents issued, 26 filed
• $3.5M investment from Tencent and
high-value funds
2015 2017 2019
2016 2018
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc.
4
I n n o v e g a

5. Market Opportunity
Problem: Visually impaired require magnification
beyond what prescription lenses alone can provide.
Solution: Our contact lens (iOptik®) is designed to
provide optical vision correction. Matching
lightweight display eyewear equipped with a camera
delivers a magnified and panoramic view.
Size: 120 million visually impaired and legally blind
patients worldwide — We estimate this to become a
$15B global market.
$15B
Visually Impaired
Problem: Consumer AR and VR eyewear require
bulky lenses to provide panoramic, high-resolution
experiences.
Solution: Remove bulky lenses and replace them with
next-generation contact lenses that are matched to
normal, stylish display eyewear.
Size: Global AR and VR forecast at USD $31B by 2023.
$31B
AR and VR Smart Glasses
by 2023
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 5
I n n o v e g a

6. The Problem: Humans expect STYLISH
and Comfortable GLASSES
VS
Innovega
I n n o v e g a

7. Our Product
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 7
Users will wear
contact lenses
and eyewear
User will see a
high-resolution
panoramic view
I n n o v e g a

8. Revenue Model
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 8
NRE fees could be seven
figures or more.
NRE are one-time fees to
develop, design or
manufacture a new product
for a new licensee partner.
I n n o v e g a
Multiple revenue streams:
Upfront license fees; future
royalties based on sales or
profits; non-recurring
engineering (NRE) fees to
fund Innovega
collaboration.
Upfront license fees could
be eight figures or more.
Licenses of intellectual
property to eyewear and
contact lens manufacturers;
and to distributors who will
sell and market the
combined system.
Glasses royalties could be a
percentage of a suggested
$3,000 cost to the patient.
Contact lens royalties could
be a percentage of
recurring revenue from
disposable lenses.

9. Marketing and Growth Strategy
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 9
Our strategy: Deliver patient and consumer experiences well beyond our competitors
The market wants many
configurations and applications
The market wants high
performance
The market wants comfort
Sales channels: Visually Impaired and Legally Blind | Dental and Surgical Visualization | Consumer Markets
Our design objectives:
• Lightweight, balanced (2-3 oz.)
• No eyestrain or headaches
• Vision correction
• Any style, normal glasses
Our design objectives:
• High resolution
• Panoramic
• Highest image quality
Our design objectives:
• VR/AR
• Any image source
• Expandable and extendable
I n n o v e g a

10. Management Team
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 10
Steve Willey: Co-Founder, CEO & Director — Passion for commercializing game-
changing technologies; Co-founder and president, MicroVision (NASDAQ: MVIS);
turnaround CEO of AirIQ Inc (TSXV:IQ); multiple business and general management of
startups that were later acquired by Fortune 100 companies.
Dr. Jerome A. Legerton: Co-Founder, Director — Successful career in contact lens
development and commercialization; 57 issued U.S. patents, co-inventor of Paragon CRT®
contact lenses, the market leader for overnight corneal reshaping. Co-founder and former
CTO and EVP of SynergEyes, Inc., the world leader in hybrid contact lenses.
Jay Marsh: VP Engineering — Former VP Engineering with APRI, and more than 25
years developing systems that achieved unprecedented performance; leadership of
multidisciplinary engineering teams dedicated to delivering complex electro / optical /
mechanical systems.
I n n o v e g a

11. Pro-Forma Forecast
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 11
2020 – Non-Recurring Engineering Fees (NRE) and Licenses: $2M
2021 – NRE, Licenses and Royalties: $5M
2022 – NRE, Licenses and Royalties: $12M with $5M EBITDA
202220212020
$2M
Revenue
$5M
Revenue
$12M
Revenue
$5M
EBITDA

12. Competition
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 12
• Oculus – too bulky, not stylish
• PlayStation VR – too bulky, not stylish
• HTC – too bulky, not stylish
• eSight – too bulky, not stylish, small field of view
• VES-Falcon Autofocus Bioptic – small field of
view, not stylish
• IrisVision – too bulky, not stylish
Eyewear for Visually Impaired Eyewear for AR / VR
I n n o v e g a

13. 35%
15%
30%
5%
10%
5%
Prototypes
Commercialization
of Contact Lens
Reg A
Offering
Expenses
Capital
equipment
Investment – Convertible Note
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 13
FDA Phase III
for Contact
Lens
Commercialization
of Eyewear
• Future conversion to stock at a 20% discount
to price paid by future investors
• Earns 5% rate of interest
• Maximum price at time of future conversion
capped at $32M
Existing Investors:
• 24-month term, $5M Maximum Investment
• Completed Phase I in May 2019 ($1M)-
Deployed Funds in April-November 2019
• Phase II: Close in November 2019 ($1.5M)
• Phase III: Close in Q1 2020 ($2.5M)
Use of Proceeds
I n n o v e g a

14. Thanks and Attribution
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 14
Management thanks DARPA-NSF-NEI
program managers, clinical investigators
from The Ohio State University, our
amazing staff and advisors, and our nearly
200 shareholders who have supported our
vision to contribute to the health, quality of
life and enjoyment of the human race.
I n n o v e g a

15. Contact
COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and
iOptik is a registered trademark, of Innovega Inc. 15
425-516-8175
IR@Innovega-inc.com
I n n o v e g a